Ipsen Deal History & Licensing Activity
Ipsen is a large pharma headquartered in France. The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
50
Top Modality
N/A
Focus Area
Solid Tumors
Ipsen Pipeline Focus
Therapeutic areas and modalities where Ipsen is most active based on deal history and clinical trial data.
Therapeutic Areas
Ipsen Strategic Signals
Key indicators of Ipsen's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Ipsen Clinical Pipeline
Ipsen has 50 active clinical trials across 6 development phases.
18
Unknown
2
Not Applicable
1
Phase 4
8
Phase 1
10
Phase 2
11
Phase 3
See How Your Asset Matches Ipsen's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
About Ipsen Licensing & Deal Activity
Ipsen is a large pharma company based in France that has been actively engaged in licensing transactions across the biopharma landscape.
Key therapeutic areas of focus for Ipsen include Solid Tumors (13 deals and trials), CNS Disorders (5 deals and trials), Hematological Malignancies (4 deals and trials), and Metabolic (1 deal and trial).
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Ipsen and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Ipsen's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.